These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30424709)

  • 1. "TRPV1 is a component of the atrial natriuretic signaling complex, and using orally delivered antagonists, presents a valid therapeutic target in the longitudinal reversal and treatment of cardiac hypertrophy and heart failure".
    Horton JS; Shiraishi T; Alfulaij N; Small-Howard AL; Turner HC; Kurokawa T; Mori Y; Stokes AJ
    Channels (Austin); 2019 Dec; 13(1):1-16. PubMed ID: 30424709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mice lacking functional TRPV1 are protected from pressure overload cardiac hypertrophy.
    Buckley CL; Stokes AJ
    Channels (Austin); 2011; 5(4):367-74. PubMed ID: 21814047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful TRPV1 antagonist treatment for cardiac hypertrophy and heart failure in mice.
    Horton JS; Buckley CL; Stokes AJ
    Channels (Austin); 2013 Jan; 7(1):17-22. PubMed ID: 23221478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitogen-Activated Protein Kinase and Intracellular Polyamine Signaling Is Involved in TRPV1 Activation-Induced Cardiac Hypertrophy.
    Chen M; Xin J; Liu B; Luo L; Li J; Yin W; Li M
    J Am Heart Assoc; 2016 Jul; 5(8):. PubMed ID: 27473037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic ablation of TRPV1 exacerbates pressure overload-induced cardiac hypertrophy.
    Zhong B; Rubinstein J; Ma S; Wang DH
    Biomed Pharmacother; 2018 Mar; 99():261-270. PubMed ID: 29334670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cold stress accentuates pressure overload-induced cardiac hypertrophy and contractile dysfunction: role of TRPV1/AMPK-mediated autophagy.
    Lu S; Xu D
    Biochem Biophys Res Commun; 2013 Dec; 442(1-2):8-15. PubMed ID: 24211590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.
    Takimoto E; Champion HC; Li M; Belardi D; Ren S; Rodriguez ER; Bedja D; Gabrielson KL; Wang Y; Kass DA
    Nat Med; 2005 Feb; 11(2):214-22. PubMed ID: 15665834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-A signaling in the heart.
    Kinoshita H; Kuwahara K; Nishida M; Jian Z; Rong X; Kiyonaka S; Kuwabara Y; Kurose H; Inoue R; Mori Y; Li Y; Nakagawa Y; Usami S; Fujiwara M; Yamada Y; Minami T; Ueshima K; Nakao K
    Circ Res; 2010 Jun; 106(12):1849-60. PubMed ID: 20448219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac-specific overexpression of caveolin-3 attenuates cardiac hypertrophy and increases natriuretic peptide expression and signaling.
    Horikawa YT; Panneerselvam M; Kawaraguchi Y; Tsutsumi YM; Ali SS; Balijepalli RC; Murray F; Head BP; Niesman IR; Rieg T; Vallon V; Insel PA; Patel HH; Roth DM
    J Am Coll Cardiol; 2011 May; 57(22):2273-83. PubMed ID: 21616289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response.
    Beider K; Rosenberg E; Dimenshtein-Voevoda V; Sirovsky Y; Vladimirsky J; Magen H; Ostrovsky O; Shimoni A; Bromberg Z; Weiss L; Peled A; Nagler A
    J Hematol Oncol; 2020 Nov; 13(1):158. PubMed ID: 33239060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficiency of Cardiac Natriuretic Peptide Signaling Promotes Peripartum Cardiomyopathy-Like Remodeling in the Mouse Heart.
    Otani K; Tokudome T; Kamiya CA; Mao Y; Nishimura H; Hasegawa T; Arai Y; Kaneko M; Shioi G; Ishida J; Fukamizu A; Osaki T; Nagai-Okatani C; Minamino N; Ensho T; Hino J; Murata S; Takegami M; Nishimura K; Kishimoto I; Miyazato M; Harada-Shiba M; Yoshimatsu J; Nakao K; Ikeda T; Kangawa K
    Circulation; 2020 Feb; 141(7):571-588. PubMed ID: 31665900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRPV1-antagonist AMG9810 promotes mouse skin tumorigenesis through EGFR/Akt signaling.
    Li S; Bode AM; Zhu F; Liu K; Zhang J; Kim MO; Reddy K; Zykova T; Ma WY; Carper AL; Langfald AK; Dong Z
    Carcinogenesis; 2011 May; 32(5):779-85. PubMed ID: 21349818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Complement System Component C5a Produces Thermal Hyperalgesia via Macrophage-to-Nociceptor Signaling That Requires NGF and TRPV1.
    Shutov LP; Warwick CA; Shi X; Gnanasekaran A; Shepherd AJ; Mohapatra DP; Woodruff TM; Clark JD; Usachev YM
    J Neurosci; 2016 May; 36(18):5055-70. PubMed ID: 27147658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased transient receptor potential vanilloid type 1 (TRPV1) channel expression in hypertrophic heart.
    Thilo F; Liu Y; Schulz N; Gergs U; Neumann J; Loddenkemper C; Gollasch M; Tepel M
    Biochem Biophys Res Commun; 2010 Oct; 401(1):98-103. PubMed ID: 20833132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient Receptor Potential Vanilloid Type 1 Protects Against Pressure Overload-Induced Cardiac Hypertrophy by Promoting Mitochondria-Associated Endoplasmic Reticulum Membranes.
    Wang Y; Li X; Xu X; Qu X; Yang Y
    J Cardiovasc Pharmacol; 2022 Sep; 80(3):430-441. PubMed ID: 35881904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of PKG-1α Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation.
    Nakamura T; Zhu G; Ranek MJ; Kokkonen-Simon K; Zhang M; Kim GE; Tsujita K; Kass DA
    Circ Heart Fail; 2018 Mar; 11(3):e004740. PubMed ID: 29545395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sympathetic nervous system is controlled by transient receptor potential vanilloid 1 in the regulation of body temperature.
    Alawi KM; Aubdool AA; Liang L; Wilde E; Vepa A; Psefteli MP; Brain SD; Keeble JE
    FASEB J; 2015 Oct; 29(10):4285-98. PubMed ID: 26136480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic antagonism of the oral aversive taste-directed response to capsaicin in a mouse brief access taste aversion assay.
    Long DJ; Devantier HR; Brennan FX; Bryant RW; Salemme FR; Palmer RK
    J Pharmacol Exp Ther; 2010 Feb; 332(2):525-30. PubMed ID: 19903834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling.
    Franco V; Chen YF; Oparil S; Feng JA; Wang D; Hage F; Perry G
    Hypertension; 2004 Nov; 44(5):746-50. PubMed ID: 15452027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.
    Nakagawa H; Oberwinkler H; Nikolaev VO; Gaßner B; Umbenhauer S; Wagner H; Saito Y; Baba HA; Frantz S; Kuhn M
    Circ Heart Fail; 2014 Sep; 7(5):814-21. PubMed ID: 25027872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.